Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Gastroenterol Hepatol ; 47(7): 711-720, 2024.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-38160706

RESUMO

OBJECTIVES: In Latin America, experience with monitoring serum Infliximab (IFX) concentrations is scarce. Our study aimed to compare IFX serum concentrations between patients with active disease or in remission. PATIENTS AND METHODS: A cross-sectional study was performed in patients with luminal Crohn's disease (CD) during maintenance treatment with IFX. Patients were classified as in remission or disease activity according to clinical scores and endoscopic, radiological, and laboratory markers. A comparison of IFX trough levels between the two groups was performed. RESULTS: 80 CD patients were included [41 (51%) in remission and 39 (49%) with active disease]. In the analysis of general disease activity, the median serum levels of IFX in patients with remission and with active CD were 5.63 [0.03-14.40] vs. 3.84 [0.03-14.40] (p=0.287). Furthermore, there was no difference in serum IFX concentrations in endoscopic, radiological, and laboratory activities. Only in the clinical evaluation there was a significant difference in the median serum IFX levels between patients in remission and disease activity, 5.63 [0.03-14.40] vs. 2.14 [0.32-10.54] (p=0.042). CONCLUSIONS: IFX serum concentrations during maintenance treatment were similar in patients with luminal CD in remission and general, endoscopic, radiological, and laboratory disease activity. Patients with clinically active disease had lower IFX concentrations than patients in remission.


Assuntos
Doença de Crohn , Fármacos Gastrointestinais , Infliximab , Humanos , Doença de Crohn/tratamento farmacológico , Doença de Crohn/sangue , Infliximab/sangue , Infliximab/uso terapêutico , Infliximab/farmacocinética , Estudos Transversais , Masculino , Feminino , Adulto , Fármacos Gastrointestinais/sangue , Fármacos Gastrointestinais/uso terapêutico , Fármacos Gastrointestinais/farmacocinética , Indução de Remissão , Adulto Jovem , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Monitoramento de Medicamentos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...